Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
, 58 (105), 246-50

The Trends of One-Week First-Line and Second-Line Eradication Therapy for Helicobacter Pylori Infection in Korea

Affiliations
  • PMID: 21510323
Comparative Study

The Trends of One-Week First-Line and Second-Line Eradication Therapy for Helicobacter Pylori Infection in Korea

Jun-Won Chung et al. Hepatogastroenterology.

Abstract

Background/aims: Increasing levels of bacterial antibiotic resistance raise the need to assess the eradication efficiency of Helicobacter pylori. The aim of this study was to evaluate 7-year changes in efficacy of one-week first line and second line therapies in Helicobacter pylori eradication rates in Korea.

Methodology: From 2001 to 2007, 4198 Helicobacter pylori-positive patients received first-line therapy (proton pump inhibitor, amoxicillin 1,000 mg b.i.d., and clarithromycin 500 mg b.i.d.). Four hundred ninety patients received second-line therapy (proton pump inhibitor twelve hourly, metronidazole 500 mg t.i.d., tetracycline 500 mg q.i.d., and bismuth 300 mg q.i.d.). A 13C-urea breath test was used to determine the eradication rate.

Results: The eradication rates of first-line therapy were 81.3%, 83.7%, 80.1%, 80.7%, 82.0%, 75.9%, and 77.5% from 2001 to 2007, with a decreasing trend (p < 0.01). The eradication rate of second-line therapy was 77.3%, 86.2%, 95.6%, 95.9%, 89.6%, 83.2%, and 86.4% from 2001 to 2007 without decreasing trend (p = 0.26).

Conclusions: The eradication rate of first-line therapy has decreased in the last 7 years while that of second-line therapy has remained the same. A new strategy is required to improve the first-line therapy for Helicobacter pylori eradication in Korea.

Similar articles

See all similar articles

Cited by 16 PubMed Central articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback